{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:16:03Z","timestamp":1777392963045,"version":"3.51.4"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Talent Reserve Program","award":["JDYYCB-2023007"],"award-info":[{"award-number":["JDYYCB-2023007"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82370153"],"award-info":[{"award-number":["82370153"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Development Project of Jilin Province","award":["YDZJ202201ZYTS606"],"award-info":[{"award-number":["YDZJ202201ZYTS606"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s00277-025-06618-1","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T07:35:42Z","timestamp":1758872142000},"page":"4549-4564","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Internal tandem duplications of FLT3 containing exogenous sequences are associated with poor clinical outcomes in acute myeloid leukemia"],"prefix":"10.1007","volume":"104","author":[{"given":"Shao-Tong","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiu-Min","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiu-Ju","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye-Hui","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Ping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-Nan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Long","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su-Jun","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"issue":"3","key":"6618_CR1","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/ajh.26822","volume":"98","author":"S Shimony","year":"2023","unstructured":"Shimony S, Stahl M, Stone RM (2023) Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol 98(3):502\u2013526. https:\/\/doi.org\/10.1002\/ajh.26822","journal-title":"Am J Hematol"},{"key":"6618_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2147\/ott.S236740","volume":"16","author":"S Garciaz","year":"2023","unstructured":"Garciaz S, Hospital MA (2023) FMS-like tyrosine kinase 3 inhibitors in the treatment of acute myeloid leukemia: an update on the emerging evidence and safety profile. Onco Targets Ther 16:31\u201345. https:\/\/doi.org\/10.2147\/ott.S236740","journal-title":"Onco Targets Ther"},{"issue":"1","key":"6618_CR3","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1080\/16078454.2019.1666219","volume":"24","author":"X Hu","year":"2019","unstructured":"Hu X, Chen F (2019) Targeting on glycosylation of mutant FLT3 in acute myeloid leukemia. Hematol (Amsterdam Netherlands) 24(1):651\u2013660. https:\/\/doi.org\/10.1080\/16078454.2019.1666219","journal-title":"Hematol (Amsterdam Netherlands)"},{"key":"6618_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14235799","author":"R Ayala","year":"2022","unstructured":"Ayala R, Carre\u00f1o-Tarragona G, Barrag\u00e1n E, Boluda B, Larr\u00e1yoz MJ, Chill\u00f3n MC, Carrillo-Cruz E, Bilbao C, S\u00e1nchez-Garc\u00eda J, Bernal T, Martinez-Cuadron D, Gil C, Serrano J, Rodriguez-Medina C, Bergua J, P\u00e9rez-Sim\u00f3n JA, Calbacho M, Alonso-Dom\u00ednguez JM, Labrador J, Tormo M, Amigo ML, Herrera-Puente P, Rapado I, Sargas C, Vazquez I, Calasanz MJ, Gomez-Casares T, Garc\u00eda-Sanz R, Sanz MA, Mart\u00ednez-L\u00f3pez J, Montesinos P (2022) Impact of FLT3-ITD mutation status and its ratio in a cohort of 2901 patients undergoing upfront intensive chemotherapy: a PETHEMA registry study. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers14235799","journal-title":"Cancers (Basel)"},{"issue":"10388","key":"6618_CR5","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/s0140-6736(23)00464-6","volume":"401","author":"HP Erba","year":"2023","unstructured":"Erba HP, Montesinos P, Kim HJ, Patkowska E, Vrhovac R, \u017d\u00e1k P, Wang PN, Mitov T, Hanyok J, Kamel YM, Rohrbach JEC, Liu L, Benzohra A, Lesegretain A, Cortes J, Perl AE, Sekeres MA, Dombret H, Amadori S, Wang J, Levis MJ, Schlenk RF (2023) Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London England) 401(10388):1571\u20131583. https:\/\/doi.org\/10.1016\/s0140-6736(23)00464-6","journal-title":"Lancet (London England)"},{"issue":"5","key":"6618_CR6","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, D\u00f6hner K, Marcucci G, Lo-Coco F, Klisovic RB, Wei A, Sierra J, Sanz MA, Brandwein JM, de Witte T, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Krauter J, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Larson RA, D\u00f6hner H (2017) Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med 377(5):454\u2013464. https:\/\/doi.org\/10.1056\/NEJMoa1614359","journal-title":"N Engl J Med"},{"issue":"1","key":"6618_CR7","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1038\/s41467-023-37381-4","volume":"14","author":"H Wang","year":"2023","unstructured":"Wang H, Luo G, Hu X, Xu G, Wang T, Liu M, Qiu X, Li J, Fu J, Feng B, Tu Y, Kan W, Wang C, Xu R, Zhou Y, Yang J, Li J (2023) Targeting C\/EBP\u03b1 overcomes primary resistance and improves the efficacy of FLT3 inhibitors in acute myeloid leukaemia. Nat Commun 14(1):1882. https:\/\/doi.org\/10.1038\/s41467-023-37381-4","journal-title":"Nat Commun"},{"key":"6618_CR8","doi-asserted-by":"publisher","unstructured":"Lin D, Wei H, Wang Y, Zhou CL, Liu BC, Liu KQ, Gong BF, Wei SN, Zhang GJ, Liu YT, Gong XY, Qiu SW, Mi YC, Wang JX (2016) [The clinical and prognostic significance of acute myeloid leukemia with FLT3-ITD]. Zhonghua Xue ye Xue Za zhi\u2009=\u2009zhonghua Xueyexue Zazhi 37:121017\u20131021. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2016.12.001","DOI":"10.3760\/cma.j.issn.0253-2727.2016.12.001"},{"issue":"13","key":"6618_CR9","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1182\/blood-2002-05-1440","volume":"100","author":"S Fr\u00f6hling","year":"2002","unstructured":"Fr\u00f6hling S, Schlenk RF, Breitruck J, Benner A, Kreitmeier S, Tobis K, D\u00f6hner H, D\u00f6hner K (2002) Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML study group Ulm. Blood 100(13):4372\u20134380. https:\/\/doi.org\/10.1182\/blood-2002-05-1440","journal-title":"Blood"},{"issue":"1","key":"6618_CR10","doi-asserted-by":"publisher","first-page":"36","DOI":"10.5045\/kjh.2010.45.1.36","volume":"45","author":"YK Kim","year":"2010","unstructured":"Kim YK, Kim HN, Lee SR, Ahn JS, Yang DH, Lee JJ, Lee IK, Shin MG, Kim HJ (2010) Prognostic significance of nucleophosmin mutations and FLT3 internal tandem duplication in adult patients with cytogenetically normal acute myeloid leukemia. Korean J Hematol 45(1):36\u201345. https:\/\/doi.org\/10.5045\/kjh.2010.45.1.36","journal-title":"Korean J Hematol"},{"issue":"7","key":"6618_CR11","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.bbmt.2016.03.027","volume":"22","author":"B Oran","year":"2016","unstructured":"Oran B, Cortes J, Beitinjaneh A, Chen HC, de Lima M, Patel K, Ravandi F, Wang X, Brandt M, Andersson BS, Ciurea S, Santos FP, de Padua Silva L, Shpall EJ, Champlin RE, Kantarjian H, Borthakur G (2016) Allogeneic transplantation in first remission improves outcomes irrespective of FLT3-ITD allelic ratio in FLT3-ITD-positive acute myelogenous leukemia. Biol Blood Marrow Transplant 22(7):1218\u20131226. https:\/\/doi.org\/10.1016\/j.bbmt.2016.03.027","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"6618_CR12","doi-asserted-by":"publisher","first-page":"158","DOI":"10.4274\/tjh.2018.0017","volume":"35","author":"MT Ardestani","year":"2018","unstructured":"Ardestani MT, Kazemi A, Chahardouli B, Mohammadi S, Nikbakht M, Rostami S, Jalili M, Vaezi M, Alimoghaddam K, Ghavamzadeh A (2018) FLT3-ITD compared with DNMT3A R882 mutation is a more powerful independent inferior prognostic factor in adult acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation: a retrospective cohort study. Turkish J Haematology: Official J Turkish Soc Haematol 35(3):158\u2013167. https:\/\/doi.org\/10.4274\/tjh.2018.0017","journal-title":"Turkish J Haematology: Official J Turkish Soc Haematol"},{"issue":"8","key":"6618_CR13","doi-asserted-by":"publisher","first-page":"e600","DOI":"10.1016\/s2352-3026(23)00117-5","volume":"10","author":"L Xuan","year":"2023","unstructured":"Xuan L, Wang Y, Yang K, Shao R, Huang F, Fan Z, Chi P, Xu Y, Xu N, Deng L, Li X, Liang X, Luo X, Shi P, Liu H, Wang Z, Jiang L, Lin R, Chen Y, Tu S, Zhang Y, Sun J, Huang X, Liu Q (2023) Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol 10(8):e600\u2013e611. https:\/\/doi.org\/10.1016\/s2352-3026(23)00117-5","journal-title":"Lancet Haematol"},{"issue":"4","key":"6618_CR14","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/bmt.2015.170","volume":"51","author":"Y Song","year":"2016","unstructured":"Song Y, Magenau J, Li Y, Braun T, Chang L, Bixby D, Hanauer DA, Chughtai KA, Gatza E, Couriel D, Goldstein S, Pawarode A, Reddy P, Riwes M, Connelly J, Harris A, Kitko C, Levine J, Yanik G, Parkin B, Choi SW (2016) FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML. Bone Marrow Transplant 51(4):511\u2013520. https:\/\/doi.org\/10.1038\/bmt.2015.170","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"6618_CR15","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1182\/blood-2016-07-730648","volume":"129","author":"S Knapper","year":"2017","unstructured":"Knapper S, Russell N, Gilkes A, Hills RK, Gale RE, Cavenagh JD, Jones G, Kjeldsen L, Grunwald MR, Thomas I, Konig H, Levis MJ, Burnett AK (2017) A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML. Blood 129(9):1143\u20131154. https:\/\/doi.org\/10.1182\/blood-2016-07-730648","journal-title":"Blood"},{"issue":"6","key":"6618_CR16","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3892\/mco.2024.2791","volume":"21","author":"WT Lin","year":"2024","unstructured":"Lin WT, Chao CM, Lin CY, Hsu YT, Hsiao SY, Weng TS (2024) Efficacy and safety of second\u2013generation FLT3 inhibitors in acute myeloid leukemia: a systematic review and meta\u2013analysis of randomized controlled trials. Mol Clin Oncol 21(6):93. https:\/\/doi.org\/10.3892\/mco.2024.2791","journal-title":"Mol Clin Oncol"},{"key":"6618_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.686013","volume":"11","author":"Q Xu","year":"2021","unstructured":"Xu Q, He S, Yu L (2021) Clinical benefits and safety of FMS-like tyrosine kinase 3 inhibitors in various treatment stages of acute myeloid leukemia: a systematic review, meta-analysis, and network meta-analysis. Front Oncol 11:686013. https:\/\/doi.org\/10.3389\/fonc.2021.686013","journal-title":"Front Oncol"},{"issue":"5","key":"6618_CR18","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41408-021-00495-3","volume":"11","author":"N Daver","year":"2021","unstructured":"Daver N, Venugopal S, Ravandi F (2021) FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm. Blood Cancer J 11(5):104. https:\/\/doi.org\/10.1038\/s41408-021-00495-3","journal-title":"Blood Cancer J"},{"issue":"5","key":"6618_CR19","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1182\/blood-2007-08-109090","volume":"111","author":"RE Gale","year":"2008","unstructured":"Gale RE, Green C, Allen C, Mead AJ, Burnett AK, Hills RK, Linch DC (2008) The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 111(5):2776\u20132784. https:\/\/doi.org\/10.1182\/blood-2007-08-109090","journal-title":"Blood"},{"issue":"5","key":"6618_CR20","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41408-020-0318-1","volume":"10","author":"I Abou Dalle","year":"2020","unstructured":"Abou Dalle I, Ghorab A, Patel K, Wang X, Hwang H, Cortes J, Issa GC, Yalniz F, Sasaki K, Chihara D, Price A, Kadia T, Pemmaraju N, Daver N, DiNardo C, Ravandi F, Kantarjian HM, Borthakur G (2020) Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia. Blood Cancer J 10(5):48. https:\/\/doi.org\/10.1038\/s41408-020-0318-1","journal-title":"Blood Cancer J"},{"issue":"5","key":"6618_CR21","first-page":"1161","volume":"19","author":"L Ma","year":"2011","unstructured":"Ma L, Feng DR, Zhong MH, Wang LW, Cai Y, Ma YG, Huang SZ (2011) Analysis of ITD characteristics in acute myeloid leukemia patients with FLT3-ITD positive. Zhongguo shi yan xue ye xue za zhi 19(5):1161\u20131165","journal-title":"Zhongguo shi yan xue ye xue za zhi"},{"issue":"4","key":"6618_CR22","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, L\u00f6wenberg B, Bloomfield CD (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424\u2013447. https:\/\/doi.org\/10.1182\/blood-2016-08-733196","journal-title":"Blood"},{"issue":"3","key":"6618_CR23","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.bbmt.2015.10.023","volume":"22","author":"AD Ho","year":"2016","unstructured":"Ho AD, Schetelig J, Bochtler T, Schaich M, Sch\u00e4fer-Eckart K, H\u00e4nel M, R\u00f6sler W, Einsele H, Kaufmann M, Serve H, Berdel WE, Stelljes M, Mayer J, Reichle A, Baldus CD, Schmitz N, Kramer M, R\u00f6llig C, Bornh\u00e4user M, Thiede C, Ehninger G (2016) Allogeneic stem cell transplantation improves survival in patients with acute myeloid leukemia characterized by a high allelic ratio of mutant FLT3-ITD. Biol Blood Marrow Transplant 22(3):462\u2013469. https:\/\/doi.org\/10.1016\/j.bbmt.2015.10.023","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"6618_CR24","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1182\/blood-2014-02-554667","volume":"124","author":"DC Linch","year":"2014","unstructured":"Linch DC, Hills RK, Burnett AK, Khwaja A, Gale RE (2014) Impact of FLT3(ITD) mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia. Blood 124(2):273\u2013276. https:\/\/doi.org\/10.1182\/blood-2014-02-554667","journal-title":"Blood"},{"issue":"23","key":"6618_CR25","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1182\/blood-2014-05-578070","volume":"124","author":"RF Schlenk","year":"2014","unstructured":"Schlenk RF, Kayser S, Bullinger L, Kobbe G, Casper J, Ringhoffer M, Held G, Brossart P, L\u00fcbbert M, Salih HR, Kindler T, Horst HA, Wulf G, Nachbaur D, G\u00f6tze K, Lamparter A, Paschka P, Gaidzik VI, Teleanu V, Sp\u00e4th D, Benner A, Krauter J, Ganser A, D\u00f6hner H, D\u00f6hner K (2014) Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. Blood 124(23):3441\u20133449. https:\/\/doi.org\/10.1182\/blood-2014-05-578070","journal-title":"Blood"},{"issue":"14","key":"6618_CR26","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1182\/blood-2012-06-431122","volume":"121","author":"M Pratcorona","year":"2013","unstructured":"Pratcorona M, Brunet S, Nomded\u00e9u J, Ribera JM, Tormo M, Duarte R, Escoda L, Gu\u00e0rdia R, Queipo de Llano MP, Salamero O, Bargay J, Pedro C, Mart\u00ed JM, Torrebadell M, D\u00edaz-Bey\u00e1 M, Cam\u00f3s M, Colomer D, Hoyos M, Sierra J, Esteve J (2013) Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. Blood 121(14):2734\u20132738. https:\/\/doi.org\/10.1182\/blood-2012-06-431122","journal-title":"Blood"},{"issue":"10","key":"6618_CR27","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1038\/s41375-023-01994-x","volume":"37","author":"J Othman","year":"2023","unstructured":"Othman J, Potter N, Mokretar K, Taussig D, Khan A, Krishnamurthy P, Latif AL, Cahalin P, Aries J, Amer M, Belsham E, Conneally E, Craddock C, Culligan D, Dennis M, Duncan C, Freeman SD, Furness C, Gilkes A, Gkreka P, Hodgson K, Ingram W, Jain M, King A, Knapper S, Kottaridis P, McMullin MF, Mohite U, Ngu L, O\u2019Nions J, Patrick K, Rider T, Roberts W, Severinsen MT, Storrar N, Taylor T, Russell NH, Dillon R (2023) FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML. Leukemia 37(10):2066\u20132072. https:\/\/doi.org\/10.1038\/s41375-023-01994-x","journal-title":"Leukemia"},{"issue":"12","key":"6618_CR28","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA, Levine RL, Miyazaki Y, Niederwieser D, Ossenkoppele G, R\u00f6llig C, Sierra J, Stein EM, Tallman MS, Tien HF, Wang J, Wierzbowska A, L\u00f6wenberg B (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140(12):1345\u20131377. https:\/\/doi.org\/10.1182\/blood.2022016867","journal-title":"Blood"},{"issue":"26","key":"6618_CR29","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/blood.2021013626","volume":"138","author":"M Heuser","year":"2021","unstructured":"Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, Hourigan CS, Ngai LL, Tettero JM, Bachas C, Baer C, B\u00e9n\u00e9 MC, B\u00fccklein V, Czyz A, Denys B, Dillon R, Feuring-Buske M, Guzman ML, Haferlach T, Han L, Herzig JK, Jorgensen JL, Kern W, Konopleva MY, Lacombe F, Libura M, Majchrzak A, Maurillo L, Ofran Y, Philippe J, Plesa A, Preudhomme C, Ravandi F, Roumier C, Subklewe M, Thol F, van de Loosdrecht AA, van der Reijden BA, Venditti A, Wierzbowska A, Valk PJM, Wood BL, Walter RB, Thiede C, D\u00f6hner K, Roboz GJ, Cloos J (2021) 2021 update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD working party. Blood 138(26):2753\u20132767. https:\/\/doi.org\/10.1182\/blood.2021013626","journal-title":"Blood"},{"issue":"4","key":"6618_CR30","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s11912-023-01389-2","volume":"25","author":"R Bystrom","year":"2023","unstructured":"Bystrom R, Levis MJ (2023) An update on FLT3 in acute myeloid leukemia: pathophysiology and therapeutic landscape. Curr Oncol Rep 25(4):369\u2013378. https:\/\/doi.org\/10.1007\/s11912-023-01389-2","journal-title":"Curr Oncol Rep"},{"issue":"6","key":"6618_CR31","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1182\/blood.v98.6.1752","volume":"98","author":"PD Kottaridis","year":"2001","unstructured":"Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, Walker H, Wheatley K, Bowen DT, Burnett AK, Goldstone AH, Linch DC (2001) The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the united Kingdom medical research council AML 10 and 12 trials. Blood 98(6):1752\u20131759. https:\/\/doi.org\/10.1182\/blood.v98.6.1752","journal-title":"Blood"},{"issue":"12","key":"6618_CR32","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1182\/blood-2009-03-209999","volume":"114","author":"S Kayser","year":"2009","unstructured":"Kayser S, Schlenk RF, Londono MC, Breitenbuecher F, Wittke K, Du J, Groner S, Sp\u00e4th D, Krauter J, Ganser A, D\u00f6hner H, Fischer T, D\u00f6hner K (2009) Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. Blood 114(12):2386\u20132392. https:\/\/doi.org\/10.1182\/blood-2009-03-209999","journal-title":"Blood"},{"issue":"12","key":"6618_CR33","first-page":"4527","volume":"10","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zhao BD, Wang CC, Wang YG, Wang HF, Wang JH, Liu LX, Lou F, Cao SB, Hu XX, Huang AJ, Yang JM, Meng HT, Yu WJ, Tong HY, Wang JM, Jin J (2020) A novel prognostic scoring model for newly diagnosed FLT3-ITD-positive acute myeloid leukemia. Am J Cancer Res 10(12):4527\u20134537","journal-title":"Am J Cancer Res"},{"key":"6618_CR34","doi-asserted-by":"publisher","unstructured":"Ding S, Shen H, Chen Z, Chen S, Cen J, Ding Z, He J (2015) [ITD mutation burden for the prognosis in FLT3-ITD positive acute myeloid leukemia patients]. Zhonghua Xue ye Xue Za zhi\u2009=\u2009zhonghua Xueyexue Zazhi 36(6):449\u2013454. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2015.06.001","DOI":"10.3760\/cma.j.issn.0253-2727.2015.06.001"},{"issue":"23","key":"6618_CR35","doi-asserted-by":"publisher","first-page":"5819","DOI":"10.1002\/cncr.27571","volume":"118","author":"G Borthakur","year":"2012","unstructured":"Borthakur G, Kantarjian H, Patel KP, Ravandi F, Qiao W, Faderl S, Kadia T, Luthra R, Pierce S, Cortes JE (2012) Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia. Cancer 118(23):5819\u20135822. https:\/\/doi.org\/10.1002\/cncr.27571","journal-title":"Cancer"},{"issue":"9","key":"6618_CR36","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.1182\/blood-2005-08-3453","volume":"107","author":"DL Stirewalt","year":"2006","unstructured":"Stirewalt DL, Kopecky KJ, Meshinchi S, Engel JH, Pogosova-Agadjanyan EL, Linsley J, Slovak ML, Willman CL, Radich JP (2006) Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia. Blood 107(9):3724\u20133726. https:\/\/doi.org\/10.1182\/blood-2005-08-3453","journal-title":"Blood"},{"issue":"1","key":"6618_CR37","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.3324\/haematol.2018.191809","volume":"104","author":"SB Liu","year":"2019","unstructured":"Liu SB, Dong HJ, Bao XB, Qiu QC, Li HZ, Shen HJ, Ding ZX, Wang C, Chu XL, Yu JQ, Tao T, Li Z, Tang XW, Chen SN, Wu DP, Li L, Xue SL (2019) Impact of FLT3-ITD length on prognosis of acute myeloid leukemia. Haematologica 104(1):e9\u2013e12. https:\/\/doi.org\/10.3324\/haematol.2018.191809","journal-title":"Haematologica"},{"issue":"4","key":"6618_CR38","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/ejh.14044","volume":"111","author":"M Koo","year":"2023","unstructured":"Koo M, Song IC, Kim J, Kwon GC, Kim SY (2023) Prognostic value of the mutation types and dynamics of FLT3-ITD in acute myeloid leukemia. Eur J Haematol 111(4):562\u2013572. https:\/\/doi.org\/10.1111\/ejh.14044","journal-title":"Eur J Haematol"},{"issue":"2","key":"6618_CR39","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1158\/1078-0432.Ccr-18-0655","volume":"25","author":"GW Schwartz","year":"2019","unstructured":"Schwartz GW, Manning B, Zhou Y, Velu P, Bigdeli A, Astles R, Lehman AW, Morrissette JJD, Perl AE, Li M, Carroll M, Faryabi RB (2019) Classes of ITD predict outcomes in AML patients treated with FLT3 inhibitors. Clin Cancer Research: Official J Am Association Cancer Res 25(2):573\u2013583. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-0655","journal-title":"Clin Cancer Research: Official J Am Association Cancer Res"},{"issue":"20","key":"6618_CR40","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391\u20132405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544","journal-title":"Blood"},{"key":"6618_CR41","doi-asserted-by":"publisher","unstructured":"[Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia (not APL) (2017) ] (2017). Zhonghua xue ye xue za zhi\u2009=\u2009Zhonghua xueyexue zazhi 38 (3):177\u2013182. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2017.03.001","DOI":"10.3760\/cma.j.issn.0253-2727.2017.03.001"},{"key":"6618_CR42","doi-asserted-by":"publisher","unstructured":"[Chinese guidelines for the diagnosis and treatment of adult acute myeloid leukemia (not APL) (2021) ] (2021). Zhonghua xue ye xue za zhi\u2009=\u2009Zhonghua xueyexue zazhi 42 (8):617\u2013623. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2021.08.001","DOI":"10.3760\/cma.j.issn.0253-2727.2021.08.001"},{"key":"6618_CR43","doi-asserted-by":"publisher","unstructured":"[Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia (not APL) (2023) ] (2023). Zhonghua xue ye xue za zhi\u2009=\u2009Zhonghua xueyexue zazhi 44 (9):705\u2013712. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2023.09.001","DOI":"10.3760\/cma.j.issn.0253-2727.2023.09.001"},{"issue":"2","key":"6618_CR44","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00277-022-05033-0","volume":"102","author":"YW Zhang","year":"2023","unstructured":"Zhang YW, Su L, Tan YH, Lin H, Liu XL, Liu QJ, Sun JN, Zhang M, Du YZ, Song F, Han W, Gao SJ (2023) Measurable residual disease detected by flow cytometry independently predicts prognoses of NPM1-mutated acute myeloid leukemia. Ann Hematol 102(2):337\u2013347. https:\/\/doi.org\/10.1007\/s00277-022-05033-0","journal-title":"Ann Hematol"},{"issue":"1","key":"6618_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000279442","volume":"127","author":"AR Brothman","year":"2009","unstructured":"Brothman AR, Persons DL, Shaffer LG (2009) Nomenclature evolution: changes in the ISCN from the 2005 to the 2009 edition. Cytogenet Genome Res 127(1):1\u20134. https:\/\/doi.org\/10.1159\/000279442","journal-title":"Cytogenet Genome Res"},{"issue":"16","key":"6618_CR46","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1093\/nar\/gkq603","volume":"38","author":"K Wang","year":"2010","unstructured":"Wang K, Li M, Hakonarson H (2010) ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 38(16):e164. https:\/\/doi.org\/10.1093\/nar\/gkq603","journal-title":"Nucleic Acids Res"},{"key":"6618_CR47","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbab099","author":"D Yuan","year":"2021","unstructured":"Yuan D, He X, Han X, Yang C, Liu F, Zhang S, Luan H, Li R, He J, Duan X, Wang D, Zhou Q, Gao S, Niu B (2021) Comprehensive review and evaluation of computational methods for identifying FLT3-internal tandem duplication in acute myeloid leukaemia. Brief Bioinform. https:\/\/doi.org\/10.1093\/bib\/bbab099","journal-title":"Brief Bioinform"},{"issue":"3","key":"6618_CR48","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/bjh.18877","volume":"202","author":"SS Ge","year":"2023","unstructured":"Ge SS, Qiu QC, Dai HP, Shen XD, Wu TM, Du JH, Wan CL, Shen HJ, Wu DP, Xue SL, Liu SB (2023) Mutation spectrum of FLT3 and significance of non-canonical FLT3 mutations in haematological malignancy. Br J Haematol 202(3):539\u2013549. https:\/\/doi.org\/10.1111\/bjh.18877","journal-title":"Br J Haematol"},{"issue":"13","key":"6618_CR49","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1200\/jco.23.01911","volume":"42","author":"NJ Short","year":"2024","unstructured":"Short NJ, Daver N, Dinardo CD, Kadia T, Nasr LF, Macaron W, Yilmaz M, Borthakur G, Montalban-Bravo G, Garcia-Manero G, Issa GC, Chien KS, Jabbour E, Nasnas C, Huang X, Qiao W, Matthews J, Stojanik CJ, Patel KP, Abramova R, Thankachan J, Konopleva M, Kantarjian H, Ravandi F (2024) Azacitidine, venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3-mutated AML. J Clin Oncology: Official J Am Soc Clin Oncol 42(13):1499\u20131508. https:\/\/doi.org\/10.1200\/jco.23.01911","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"10","key":"6618_CR50","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1002\/gcc.21975","volume":"51","author":"S Schnittger","year":"2012","unstructured":"Schnittger S, Bacher U, Haferlach C, Alpermann T, Kern W, Haferlach T (2012) Diversity of the juxtamembrane and TKD1 mutations (exons 13\u201315) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data. Genes Chromosomes Cancer 51(10):910\u2013924. https:\/\/doi.org\/10.1002\/gcc.21975","journal-title":"Genes Chromosomes Cancer"},{"issue":"11","key":"6618_CR51","first-page":"3031","volume":"18","author":"P Mevatee","year":"2017","unstructured":"Mevatee P, Tantiworawit A, Traisathit P, Puaninta C, Mevatee U, Angsuchawan S, Bumroongkit K (2017) FLT3-ITD, NPM1, and DNMT3A gene mutations and risk factors in normal karyotype acute myeloid leukemia and myelodysplastic syndrome patients in upper Northern Thailand. Asian Pac J Cancer Prevention: APJCP 18(11):3031\u20133039","journal-title":"Asian Pac J Cancer Prevention: APJCP"},{"issue":"1","key":"6618_CR52","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41375-021-01323-0","volume":"36","author":"FG R\u00fccker","year":"2022","unstructured":"R\u00fccker FG, Du L, Luck TJ, Benner A, Krzykalla J, Gathmann I, Voso MT, Amadori S, Prior TW, Brandwein JM, Appelbaum FR, Medeiros BC, Tallman MS, Savoie L, Sierra J, Pallaud C, Sanz MA, Jansen JH, Niederwieser D, Fischer T, Ehninger G, Heuser M, Ganser A, Bullinger L, Larson RA, Bloomfield CD, Stone RM, D\u00f6hner H, Thiede C, D\u00f6hner K (2022) Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. Leukemia 36(1):90\u201399. https:\/\/doi.org\/10.1038\/s41375-021-01323-0","journal-title":"Leukemia"},{"issue":"6","key":"6618_CR53","doi-asserted-by":"publisher","first-page":"e281","DOI":"10.1016\/j.clml.2019.02.001","volume":"19","author":"MM El Gammal","year":"2019","unstructured":"El Gammal MM, Ebid GT, Madney YM, Abo-Elazm OM, Kelany AK, Torra OS, Radich JP (2019) Clinical effect of combined mutations in DNMT3A, FLT3-ITD, and NPM1 among Egyptian acute myeloid leukemia patients. Clinical lymphoma, myeloma & leukemia 19(6):e281\u2013e290. https:\/\/doi.org\/10.1016\/j.clml.2019.02.001","journal-title":"Clinical lymphoma, myeloma & leukemia"},{"issue":"4","key":"6618_CR54","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1111\/cas.15720","volume":"114","author":"S Wakita","year":"2023","unstructured":"Wakita S, Marumo A, Morita K, Kako S, Toya T, Najima Y, Doki N, Kanda J, Kuroda J, Mori S, Satake A, Usuki K, Ueki T, Uoshima N, Kobayashi Y, Kawata E, Nakayama K, Nagao Y, Shono K, Shibusawa M, Tadokoro J, Hagihara M, Uchiyama H, Uchida N, Kubota Y, Kimura S, Nagoshi H, Ichinohe T, Kurosawa S, Motomura S, Hashimoto A, Muto H, Sato E, Ogata M, Mitsuhashi K, Ando J, Tashiro H, Sakaguchi M, Yui S, Arai K, Kitano T, Miyata M, Arai H, Kanda M, Itabashi K, Fukuda T, Kanda Y, Yamaguchi H (2023) Mutational analysis of DNMT3A improves the prognostic stratification of patients with acute myeloid leukemia. Cancer Sci 114(4):1297\u20131308. https:\/\/doi.org\/10.1111\/cas.15720","journal-title":"Cancer Sci"},{"key":"6618_CR55","doi-asserted-by":"publisher","unstructured":"Torabi A, Alonzo TA, Othus M, Gerbing RB, Wang YC, Ries RE, Radich JP, Appelbaum FR, O\u2019Dwyer K, Erba HP, Tallman MS, Litzow MR, Atallah EL, Luger SM, Kolb AE, Abdel-Wahab O, Stirewalt D, Levine RL, Paietta E, Meshinchi S (2022) Characteristics and prognostic effects of DNMT3A Co-Mutations. Blood 140 https:\/\/doi.org\/10.1182\/blood-2022-162526","DOI":"10.1182\/blood-2022-162526"},{"issue":"6","key":"6618_CR56","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/ijlh.14133","volume":"45","author":"M Chen","year":"2023","unstructured":"Chen M, Zeng Z, Li X, Qin W, Cai X, Chen S, Lu X (2023) Clinical features and prognostic significance of DNMT3A, FLT3, and NPM1 mutations in de novo acute myeloid leukemia patients. Int J Lab Hematol 45(6):899\u2013907. https:\/\/doi.org\/10.1111\/ijlh.14133","journal-title":"Int J Lab Hematol"},{"issue":"15","key":"6618_CR57","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1200\/jco.2017.76.3425","volume":"36","author":"SD Freeman","year":"2018","unstructured":"Freeman SD, Hills RK, Virgo P, Khan N, Couzens S, Dillon R, Gilkes A, Upton L, Nielsen OJ, Cavenagh JD, Jones G, Khwaja A, Cahalin P, Thomas I, Grimwade D, Burnett AK, Russell NH (2018) Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1 mutations. J Clin Oncology: Official J Am Soc Clin Oncol 36(15):1486\u20131497. https:\/\/doi.org\/10.1200\/jco.2017.76.3425","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"4","key":"6618_CR58","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1200\/jco.22.00715","volume":"41","author":"T Grob","year":"2023","unstructured":"Grob T, Sanders MA, Vonk CM, Kavelaars FG, Rijken M, Hanekamp DW, Gradowska PL, Cloos J, Fl\u00f8isand Y, van Marwijk Kooy M, Manz MG, Ossenkoppele GJ, Tick LW, Havelange V, L\u00f6wenberg B, Jongen-Lavrencic M, Valk PJM (2023) Prognostic value of FLT3-internal tandem duplication residual disease in acute myeloid leukemia. J Clin Oncology: Official J Am Soc Clin Oncol 41(4):756\u2013765. https:\/\/doi.org\/10.1200\/jco.22.00715","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"6618_CR59","doi-asserted-by":"publisher","unstructured":"Versluis J, In 't Hout FE, Devillier R, van Putten WL, Manz MG, Vekemans MC, Legdeur MC, Passweg JR, Maertens J, Kuball J, Biemond BJ, Valk PJ, van der Reijden BA, Meloni G, Schouten HC, Vellenga E, Pabst T, Willemze R, L\u00f6wenberg B, Ossenkoppele G, Baron F, Huls G, Cornelissen JJ (2017) Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio. Leukemia 31 (1):26\u201333. https:\/\/doi.org\/10.1038\/leu.2016.183","DOI":"10.1038\/leu.2016.183"},{"key":"6618_CR60","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024248","author":"AE Perl","year":"2024","unstructured":"Perl AE (2024) Approaching a therapeutic inflection point for FLT3-mutated AML. Blood. https:\/\/doi.org\/10.1182\/blood.2024024248","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06618-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06618-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06618-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T05:30:49Z","timestamp":1761283849000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06618-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":60,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["6618"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06618-1","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"29 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reviewed and approved by the ethics committee of Jilin University, adhering to the principles in the Declaration of Helsinki. And all the patients provided informed consent before the enrolment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}